Lower GI 2017

ART: clinical results

- Feasibility and promising results reported on the first 25 patients (Passoni Int J Rad Oncol Biol Phys 2013): 3/25 G3 GI (12%); full RT,Oxal,5FU dose in 96%, 96%, 88% of pts; no other G3 tox; 2 cCR pts refused surgery: (8%); pCR: 7/23 (30%); TRG ≥ 3: 21/23 (91%); - Major response rate (cCR+pCR+TRG3 with viable cells ≤10%): 21/25 (84%) - Updated results on 62/78 pts confirmed these results (G3 GI: 13.5%; pCR+cCR: 29%, Major response rate: 79%

- Room for further dose escalation ?

- Individualizing the ART boost based on the early response ?